FDA approves new indication for Roche’s Tecentriq
The Food and Drug Administration has cleared Roche’s Tecentriq (atezolizumab), in combination with chemotherapy, for the first-line treatment of adults with extensive-stage small-cell lung cancer.
“Tecentriq is the first cancer immunotherapy approved for the initial treatment of [extensive-stage small-cell lung cancer], which is especially difficult to treat,” Roche’s chief medical officer and head of global product development Sandra Horning said. “Until now, there have been limited treatment advances for this disease, and we are excited to bring a potential new standard of care to patients that has been shown to improve survival compared to chemotherapy.
Tecentriq is approved in combination with Avastin (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of adults with metastatic non-squamous non-small-cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Tecentriq also is approved by the FDA to treat adults with metastatic non-squamous non-small-cell lung cancer who have disease progression during or following platinum-containing chemotherapy.
No comments found